Breaks in NRG1 were detected in 6% (19 of 323) of breast cancers and in some lung and ovarian cancers.

Neuregulin 1 pathway activation is associated with lung cancer.

Results show that CD74-NRG1 gene fusions are activating genomic alterations in invasive mucinous lung adenocarcinomas.

NRG1, NF1 and Hippo pathway fusions play important roles in lung cancer.

VAMP2-NRG1 is a novel oncogenic fusion gene representing a new addition to the list of NRG1 fusion genes, which together may form an important diagnostic and clinical category of lung adenocarcinoma cases.

Data suggest that SLC3A2-NRG1 should be considered a therapeutic target for patients with invasive mucinous adenocarcinoma of the lung (IMA).

Fusions affecting NRG1 were detected in unselected lung adenocarcinomas. NRG1 fusions ranked the most prevalent fusions in common driver-negative lung adenocarcinomas from Chinese population.